Evidence map›Paper›PMID 35601120›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2022

Real-world long-term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection.

Hideki Fujii, Hiroyuki Kimura, Chitomi Hasebe, Takehiro Akahane, Takashi Satou, Atsunori Kusakabe, Yuji Kojima, Masahiko Kondo, Hiroyuki Marusawa, Haruhiko Kobashi and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 2 countries.

Hideki FujiiDepartment of Gastroenterology Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.ORCID https://orcid.org/0000-0003-1438-3690
Hiroyuki KimuraDepartment of Gastroenterology Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
Chitomi HasebeDepartment of Gastroenterology Asahikawa Red Cross Hospital Asahikawa Japan.
Takehiro AkahaneDepartment of Gastroenterology Japanese Red Cross Ishinomaki Hospital Ishinomaki Japan.
Takashi SatouDepartment of Gastroenterology Nasu Red Cross Hospital Otawara Japan.
Atsunori KusakabeDepartment of Gastroenterology Nagoya Daini Red Cross Hospital Nagoya Japan.
Yuji KojimaDepartment of Gastroenterology and Hepatology Ise Red Cross Hospital Ise Japan.
Masahiko KondoDepartment of Gastroenterology Otsu Red Cross Hospital Siga Japan.
Hiroyuki MarusawaDepartment of Gastroenterology and Hepatology Osaka Red Cross Hospital Osaka Japan.
Haruhiko KobashiDepartment of Hepatology Japanese Red Cross Okayama Hospital Okayama Japan.
Keiji TsujiDepartment of Gastroenterology Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital Hiroshima Japan.
Chikara OgawaDepartment of Gastroenterology and Hepatology Takamatsu Red Cross Hospital Takamatsu Japan.
Yasushi UchidaDepartment of Gastroenterology Matsue Red Cross Hospital Matsue Japan.
Kouji JokoCenter for Liver and Biliary Diseases Matsuyama Red Cross Hospital Ehime Japan.
Akeri MitsudaDepartment of Gastroenterology Japanese Red Cross Tottori Hospital Tottori Japan.
Masayuki KurosakiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Musashino Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology Musashino Red Cross Hospital Musashino Japan.
Kyoto first Red Cross hospital · JPMusashino Red Cross Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPIse Red Cross Hospital · JPJapanese Red Cross Asahikawa Hospital · JPJapanese Red Cross Nagoya Daini Hospital · JPMatsue Red Cross Hospital · JPMatsuyama Red Cross Hospital · JPOkayama Red Cross General Hospital · JPOsaka Red Cross Hospital · JPOtsu Red Cross Hospital · JPRed Cross Hospital · GRTakamatsu Red Cross Hospital · JPTottori University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: This study aimed to evaluate the long-term clinical course of patients achieving a sustained virologic response (SVR) with daclatasvir plus asunaprevir (DCV/ASV) therapy. Methods: A total of 911 patients who achieved SVR with DCV/ASV were assessed. To evaluate pretreatment factors contributing to hepatocellular carcinoma (HCC) after SVR, univariate and multivariate analyses were performed in all patients, in those with preexisting HCC, and in those without preexisting HCC. We selected a low-risk group of HCC cases after SVR. Finally, we evaluated liver function after achieving SVR. Results: In multivariable analyses, male sex, older age, patients with a history of HCC treatment, excess alcohol use, lower albumin, and low platelet count remained significant in the overall group; male sex and low albumin remained significant in patients with a history of HCC treatment; and male sex, older age, excess alcohol use, low platelet count, high alpha-fetoprotein (AFP), and high des-γ-carboxy prothrombin (DCP) remained significant in those without a history of HCC treatment. Patients who had not received treatment for HCC, females, those under 70 years of age, and those with platelet count ≥13 (×10 Conclusions: The incidence rate of HCC, risk factors associated with HCC, group with very low risk of developing HCC, and the clinical course in a real-world long-term study were evaluated.

Indexed as

asunaprevirdaclatasvirhepatocellular carcinoma incidenceliver function

Identifiers

PMID35601120
PMCPMC9120887
OpenAlexW4229450002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.